Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596375057> ?p ?o ?g. }
- W2596375057 endingPage "31887" @default.
- W2596375057 startingPage "31876" @default.
- W2596375057 abstract "// Anna Tejchman 1, 2 , Nathalie Lamerant-Fayel 1 , Jean-Claude Jacquinet 3 , Aleksandra Bielawska-Pohl 2 , Katarzyna Mleczko-Sanecka 1 , Catherine Grillon 1 , Salem Chouaib 4 , Maciej Ugorski 2 and Claudine Kieda 1, 5 1 Centre for Molecular Biophysics, UPR 4301 CNRS affiliated to Orléans University and INSERM, Orléans, France 2 Laboratory of Glycobiology and Intercellular Interactions, Institute of Immunology and Experimental Therapy, PAN, Wroclaw, Poland 3 ICOA, UMR CNRS 7311, University of Orleans, Orleans, France 4 INSERM U1186, Gustave Roussy Institute, Villejuif, France 5 Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland Correspondence to: Claudine Kieda, email: claudine.kieda@cnrs-orleans.fr Keywords: adhesion, cancer associated fibroblasts, CCL21, hypoxia, podoplanin Received: June 29, 2016 Accepted: October 21, 2016 Published: March 17, 2017 ABSTRACT Podoplanin (PDPN), an O-glycosylated, transmembrane, mucin-type glycoprotein, is expressed by cancer associated fibroblasts (CAFs). In malignant transformation, PDPN is subjected to changes and its role is yet to be established. Here we show that it is involved in modulating the activity of the CCL21/CCR7 chemokine/receptor axis in a hypoxia-dependent manner. In the present model, breast cancer MDA-MB-231 cells and NKL3 cells express the surface CCR7 receptor for CCL21 chemokine which is a potent chemoattractant able to bind to PDPN. The impact of the CCL21/CCR7 axis in the molecular mechanism of the adhesion of NKL3 cells and of MDA-MB-231 breast cancer cells was reduced in a hypoxic tumor environment. In addition to its known effect on migration, CCL21/CCR7 interaction was shown to allow NK cell adhesion to endothelial cells (ECs) and its reduction by hypoxia. A PDPN expressing model of CAFs made it possible to demonstrate the same CCL21/CCR7 axis involvement in the tumor cells to CAFs recognition mechanism through PDPN binding of CCL21. PDPN was induced by hypoxia and its overexpression undergoes a reduction of adhesion, making it an anti-adhesion molecule in the absence of CCL21, in the tumor. CCL21/CCR7 modulated NK cells/ECs and MDA-MB-231 cells/CAF PDPN-dependent interactions were further shown to be linked to hypoxia-dependent microRNAs as miRs: miR-210 and specifically miR-21, miR-29b which influence PDPN expression." @default.
- W2596375057 created "2017-03-23" @default.
- W2596375057 creator A5013493692 @default.
- W2596375057 creator A5013547321 @default.
- W2596375057 creator A5036163566 @default.
- W2596375057 creator A5040712491 @default.
- W2596375057 creator A5045530749 @default.
- W2596375057 creator A5056751083 @default.
- W2596375057 creator A5058317825 @default.
- W2596375057 creator A5068459130 @default.
- W2596375057 creator A5089664990 @default.
- W2596375057 date "2017-03-17" @default.
- W2596375057 modified "2023-10-15" @default.
- W2596375057 title "Tumor hypoxia modulates podoplanin/CCL21 interactions in CCR7+ NK cell recruitment and CCR7+ tumor cell mobilization" @default.
- W2596375057 cites W1539789596 @default.
- W2596375057 cites W1940339429 @default.
- W2596375057 cites W1963948079 @default.
- W2596375057 cites W1965058145 @default.
- W2596375057 cites W1984871312 @default.
- W2596375057 cites W1990313926 @default.
- W2596375057 cites W1999023229 @default.
- W2596375057 cites W2002713157 @default.
- W2596375057 cites W2003476770 @default.
- W2596375057 cites W2003566453 @default.
- W2596375057 cites W2003670869 @default.
- W2596375057 cites W2004149362 @default.
- W2596375057 cites W2009230738 @default.
- W2596375057 cites W2010353217 @default.
- W2596375057 cites W2015300224 @default.
- W2596375057 cites W2034027385 @default.
- W2596375057 cites W2035927739 @default.
- W2596375057 cites W2049174840 @default.
- W2596375057 cites W2056502071 @default.
- W2596375057 cites W2062373696 @default.
- W2596375057 cites W2070810697 @default.
- W2596375057 cites W2072178451 @default.
- W2596375057 cites W2075006530 @default.
- W2596375057 cites W2076723438 @default.
- W2596375057 cites W2084169171 @default.
- W2596375057 cites W2092280881 @default.
- W2596375057 cites W2097471654 @default.
- W2596375057 cites W2099366913 @default.
- W2596375057 cites W2102509503 @default.
- W2596375057 cites W2107184265 @default.
- W2596375057 cites W2107885651 @default.
- W2596375057 cites W2115420093 @default.
- W2596375057 cites W2122142559 @default.
- W2596375057 cites W2122393376 @default.
- W2596375057 cites W2123308947 @default.
- W2596375057 cites W2133106492 @default.
- W2596375057 cites W2133200424 @default.
- W2596375057 cites W2133428001 @default.
- W2596375057 cites W2135452173 @default.
- W2596375057 cites W2139923508 @default.
- W2596375057 cites W2150949781 @default.
- W2596375057 cites W2169612578 @default.
- W2596375057 cites W2175452743 @default.
- W2596375057 cites W2294120476 @default.
- W2596375057 cites W2294468074 @default.
- W2596375057 cites W2466063666 @default.
- W2596375057 doi "https://doi.org/10.18632/oncotarget.16311" @default.
- W2596375057 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5458255" @default.
- W2596375057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28416768" @default.
- W2596375057 hasPublicationYear "2017" @default.
- W2596375057 type Work @default.
- W2596375057 sameAs 2596375057 @default.
- W2596375057 citedByCount "26" @default.
- W2596375057 countsByYear W25963750572017 @default.
- W2596375057 countsByYear W25963750572018 @default.
- W2596375057 countsByYear W25963750572019 @default.
- W2596375057 countsByYear W25963750572020 @default.
- W2596375057 countsByYear W25963750572021 @default.
- W2596375057 countsByYear W25963750572022 @default.
- W2596375057 countsByYear W25963750572023 @default.
- W2596375057 crossrefType "journal-article" @default.
- W2596375057 hasAuthorship W2596375057A5013493692 @default.
- W2596375057 hasAuthorship W2596375057A5013547321 @default.
- W2596375057 hasAuthorship W2596375057A5036163566 @default.
- W2596375057 hasAuthorship W2596375057A5040712491 @default.
- W2596375057 hasAuthorship W2596375057A5045530749 @default.
- W2596375057 hasAuthorship W2596375057A5056751083 @default.
- W2596375057 hasAuthorship W2596375057A5058317825 @default.
- W2596375057 hasAuthorship W2596375057A5068459130 @default.
- W2596375057 hasAuthorship W2596375057A5089664990 @default.
- W2596375057 hasBestOaLocation W25963750571 @default.
- W2596375057 hasConcept C126322002 @default.
- W2596375057 hasConcept C127801297 @default.
- W2596375057 hasConcept C12823836 @default.
- W2596375057 hasConcept C13373296 @default.
- W2596375057 hasConcept C170493617 @default.
- W2596375057 hasConcept C181152851 @default.
- W2596375057 hasConcept C185592680 @default.
- W2596375057 hasConcept C186382791 @default.
- W2596375057 hasConcept C203014093 @default.
- W2596375057 hasConcept C2909316934 @default.
- W2596375057 hasConcept C502942594 @default.
- W2596375057 hasConcept C71924100 @default.
- W2596375057 hasConceptScore W2596375057C126322002 @default.